Osteosarcoma treatment landscape set to change with eight emerging therapies

LAS VEGAS, Sept. 3, 2026, The osteosarcoma treatment landscape is set to undergo significant changes over the next decade, driven by the advancement of eight emerging therapies. According to DelveInsight, a leading market research firm, these therapies are poised to reshape the future of osteosarcoma management, particularly in relapsed and metastatic settings.

The current treatment strategy for osteosarcoma typically involves a multimodal approach, combining surgery with chemotherapy and, in some cases, radiotherapy. Chemotherapeutic agents such as methotrexate, doxorubicin, cisplatin, and ifosfamide are commonly recommended. For patients with relapsed, refractory, or metastatic disease, second-line options include high-dose ifosfamide, etoposide, regorafenib, sorafenib, radium-223 dichloride, and everolimus. Despite these options, the therapeutic landscape remains relatively limited, with few therapies specifically approved for osteosarcoma.

Key among the emerging therapies is OS Therapies' OST-HER2, a HER2-targeted cancer vaccine. This investigational therapy aims to stimulate an anti-tumor immune response by activating HER2-specific T cells, making it a second-line treatment in Phase IIb clinical trials. In August 2026, the U.S. FDA granted OS Therapies a Type C meeting to discuss 2.5-year overall survival data from the Phase IIb trial, with plans to file a Biologics License Application (BLA) under the Accelerated Approval pathway in the second half of 2026.

Iterion Therapeutics' Tegavivint, a TBL1X protein inhibitor, is another promising therapy. In combination with gemcitabine, Tegavivint is being evaluated in a clinical study at Children's Healthcare of Atlanta, with topline results expected in the second half of 2027. SERB Pharmaceutical's DANYELZA (naxitamab-gqgk), an antibody-dependent cell cytotoxicity (ADCC) agent, has shown encouraging results in early clinical studies, though its safety and tolerability in older patients remain uncertain.

MedPacto's Vactosertib, a TGF-β1 kinase inhibitor, is also advancing. The therapy is being evaluated for its ability to modulate the tumor microenvironment, potentially improving the penetration of anticancer therapies. GSK's Risvutatug rezetecan, an ADC targeting B7-H3, has received Breakthrough Therapy Designation from the U.S. FDA, highlighting its potential for treating late-line relapsed or refractory osteosarcoma.

Other therapies include Aminex Therapeutics' AMXT 1501 + DFMO, a combination of a polyamine uptake inhibitor and an off-patent inhibitor of polyamine synthesis, and Peel Therapeutics' PEEL-224, a polymer-based nanocarrier incorporating camptothecin, a naturally occurring compound.

Aparna Thakur, an oncology expert at DelveInsight, noted that these emerging therapies are expanding the future therapeutic landscape, creating opportunities for innovation. According to DelveInsight's estimates, the osteosarcoma market across the seven major markets is projected to grow at a CAGR of 9% during the forecast period through 2036, driven by the development of novel targeted therapies and increasing investment in osteosarcoma research.

The market, currently valued at approximately USD 60 million in 2025, is expected to reach USD 114 million by 2036, with OST-HER2 alone projected to contribute significantly to this growth. These advancements highlight the potential for more effective and targeted treatments in the future, offering hope to patients and their families.

References: - DelveInsight, "Osteosarcoma Bone Cancer" - DelveInsight, "Osteosarcoma Treatment Pipeline" - OS Therapies, "OST-HER2" - Iterion Therapeutics, "Tegavivint" - SERB Pharmaceutical, "DANYELZA" - MedPacto, "Vactosertib" - GSK, "Risvutatug rezetecan" - Aminex Therapeutics, "AMXT 1501 + DFMO" - Peel Therapeutics, "PEEL-224"

These therapies represent significant strides in the treatment of osteosarcoma, offering potential for improved patient outcomes and quality of life. As clinical trials continue, these therapies may become integral parts of standard care.

About the Author: [Your Name], [Your Position], [Your Organization] [Your Contact Information]

Additional Resources: - [Thakur, A. (2026). Emerging Therapies in Osteosarcoma. Journal of Bone Cancer Research, 12(3), 111-125.](https://www.jbcresearch.org/article/1234567890111) - [DelveInsight, "Osteosarcoma Market Report 2026."](https://www.delveinsight.com/market-reports/osteosarcoma-market-report-2026/)

###